These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31247147)

  • 1. Statin Therapy and Lung Disorders.
    Mari PV; Lombardi F; Flore MC; Richeldi L
    Am J Respir Crit Care Med; 2019 Oct; 200(7):921-923. PubMed ID: 31247147
    [No Abstract]   [Full Text] [Related]  

  • 2. Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.
    Vedel-Krogh S; Nielsen SF; Nordestgaard BG
    PLoS One; 2015; 10(10):e0140571. PubMed ID: 26473476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.
    Kreuter M; Costabel U; Richeldi L; Cottin V; Wijsenbeek M; Bonella F; Bendstrup E; Maher TM; Wachtlin D; Stowasser S; Kolb M
    Respiration; 2018; 95(5):317-326. PubMed ID: 29414827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2014 American Thoracic Society International Conference.
    Kang S
    Lancet Respir Med; 2014 Jul; 2(7):518-20. PubMed ID: 25140364
    [No Abstract]   [Full Text] [Related]  

  • 5. Antioxidant therapy for idiopathic pulmonary fibrosis. A promising therapeutic prospect.
    Tomioka H
    Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(2):83-4. PubMed ID: 20560287
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.
    Kreuter M; Bonella F; Maher TM; Costabel U; Spagnolo P; Weycker D; Kirchgaessler KU; Kolb M
    Thorax; 2017 Feb; 72(2):148-153. PubMed ID: 27708114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of statin use in idiopathic pulmonary fibrosis.
    Santana AN; Kairalla RA; Carvalho CR
    Am J Respir Crit Care Med; 2008 May; 177(9):1048. PubMed ID: 18434336
    [No Abstract]   [Full Text] [Related]  

  • 8. Case records of the Massachusetts General Hospital. Case 14-2015. A 58-year-old woman with shortness of breath.
    Shea BS; Sharma A; Mark EJ
    N Engl J Med; 2015 Apr; 372(18):1749-58. PubMed ID: 25923555
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis.
    Yang JI; Yoon JH; Bang YJ; Lee SH; Lee SM; Byun HJ; Myung SJ; Kim W; Lee HS
    Am J Physiol Gastrointest Liver Physiol; 2010 Jan; 298(1):G126-32. PubMed ID: 19910526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
    Foody JM; Rathore SS; Galusha D; Masoudi FA; Havranek EP; Radford MJ; Krumholz HM
    J Am Geriatr Soc; 2006 Mar; 54(3):421-30. PubMed ID: 16551308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib for idiopathic pulmonary fibrosis in the Japanese population.
    Jo HE; Corte TJ
    Respirology; 2017 May; 22(4):630-631. PubMed ID: 28370834
    [No Abstract]   [Full Text] [Related]  

  • 12. Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review.
    Krishna RK; Issa O; Saha D; Macedo FY; Correal B; Santana O
    Pulm Pharmacol Ther; 2015 Feb; 30():134-40. PubMed ID: 25173913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
    Novaro GM; Tiong IY; Pearce GL; Lauer MS; Sprecher DL; Griffin BP
    Circulation; 2001 Oct; 104(18):2205-9. PubMed ID: 11684632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin and statin intolerable for some people.
    Tofield A
    Eur Heart J; 2013 Sep; 34(33):2579. PubMed ID: 24137778
    [No Abstract]   [Full Text] [Related]  

  • 16. Statin + fibrate combination therapy--fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
    Wray R; Hemsley D
    Int J Cardiol; 1999 Dec; 71(3):291. PubMed ID: 10636539
    [No Abstract]   [Full Text] [Related]  

  • 17. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
    Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
    Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Statin therapy and muscle disorders].
    Abel T; Fehér J
    Orv Hetil; 2009 Feb; 150(6):261-3. PubMed ID: 19179258
    [No Abstract]   [Full Text] [Related]  

  • 19. [Not just decreased LDL level is decisive. Which statin for patients at risk for coronary disease?].
    MMW Fortschr Med; 2004 Jun; 146(24):1-3. PubMed ID: 15366507
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.